Wuxi Biologics (Cayman) Inc. has released a presentation outlining its scaled CRDMO (Contract Research, Development, and Manufacturing Organization) platform, which supports the global advancement of biologics. The presentation details the company’s comprehensive end-to-end offerings across the biologics lifecycle, including services in monoclonal antibodies, bispecific antibodies, Fc-fusion proteins, antibody drug conjugates, viral vaccines, oncolytic viruses, virus-like particles, recombinant proteins, and antibody fragments. Key highlights include support for over 600 IND submissions globally, 25 commercial programs, and 74 Phase III projects. The company reports maintaining high reliability metrics, with a 98.3% DS success rate and a 99.6% DP success rate, and a 100% success rate in regulatory inspections by the FDA, EMA, and NMPA. Wuxi Biologics emphasizes its flexible service model, enabling global clients to access tailored contract services across research, development, and manufacturing. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief on January 11, 2026, and is solely responsible for the information contained therein.